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Abstract
■ Dopamine (DA) has been implicated in modulating multiple
cognitive control processes, including the robust maintenance
of task sets and memoranda in the face of distractors (cognitive
stability) and, conversely, the ability to switch task sets or up-
date the contents of working memory when it is advantageous
to do so (cognitive flexibility). In humans, the limited specificity
of available pharmacological probes has posed a challenge for
understanding the mechanisms by which DA, acting on multi-
ple receptor families across the PFC and striatum, differentially
influences these cognitive processes. Using a within-subject,
placebo-controlled design, we contrasted the impact of two
mechanistically distinct DA drugs, tolcapone (an inhibitor of
catechol-O-methyltransferase [COMT], a catecholamine inacti-
vator) and bromocriptine (a DA agonist with preferential affinity
for the D2 receptor), on the maintenance and switching of task
rules. Given previous work demonstrating that drug effects on
behavior are dependent on baseline DA tone, participants were
stratified according to genetic polymorphisms associated with
cortical (COMT Val158Met) and striatal (Taq1A) DA system func-
tion. Our results were partially consistent with an inverted-
U-shaped relationship between tolcapone and robust rule
maintenance (interaction with COMT genotype) and between
bromocriptine and cued rule switching (interaction with Taq1A
genotype). However, when task instructions were ambiguous,
a third relationship emerged to explain drug effects on sponta-
neous task switching (interaction of COMT genotype and bro-
mocriptine). Together, this pattern of results suggests that the
effects of DA drugs vary not only as a function of the DA system
component upon which they act but also on subtle differences
in task demands and context. ■
INTRODUCTION
To thrive in a dynamic environment, an organism must
have the capacity to rapidly switch goal-directed strate-
gies when internal demands or external contexts ren-
der the current one suboptimal. Concurrently, while a
strategy or task set remains relatively optimal, its neural
representation should be protected from decay or dis-
traction. These facets of cognitive control—cognitive
flexibility and cognitive stability, respectively—have been
linked to the actions of the neuromodulator dopamine
(DA; Ott & Nieder, 2019; Cools & D’Esposito, 2011).
However, disentangling the specific effects of DA modu-
lation on cognitive processes has been difficult because
DA acts on two different G-protein-coupled receptor clas-
ses, the D1-like (D1/D5 subtypes) and D2-like (D2/D3/
D4 subtypes) families, that are expressed to varying de-
grees throughout subcortical nuclei and layers of the
cortex and that exert opposing influences on membrane
excitability and cyclic adenosine monophosphate path-
ways. Models of DA neuromodulation have taken advan-
tage of these opposing effects, positing that actions of D1
and D2 receptors in the PFC and striatum can effectively
regulate the opposing demands of cognitive stability
and flexibility (e.g., Klanker, Feenstra, & Denys, 2013;
Durstewitz & Seamans, 2008).
Rodent and nonhuman primate research has demon-
strated an important role for PFC DA signaling in the sta-
bilization of items in working memory (Brozoski, Brown,
Rosvold, & Goldman, 1979), as well as in the mainte-
nance of more abstract representations, such as atten-
tional sets or task rules (e.g., Ellwood et al., 2017; Ott,
Jacob, & Nieder, 2014; Crofts et al., 2001). Early work
found that depletion of DA in the nonhuman primate
PFC impairs the ability to develop an attentional set
(Crofts et al., 2001) and increases susceptibility to distrac-
tion (Roberts et al., 1994). At optimal levels of DA, the D1
receptor is thought to promote robust maintenance in
working memory by enhancing the excitatory N-methyl-
D-aspartate (NMDA) receptor currents that facilitate re-
current excitation in PFC pyramidal cells and to reduce
noise from neighboring cell populations representing
competing or irrelevant stimulus (or task) features by
modulating interneuron gamma-aminobutyric acid
(GABA) receptor and hyperpolarization-activated cyclic
nucleotide-gated channel currents; these actions are
thought to enhance the signal-to-noise ratio of maintained
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neural representations (Arnsten, Wang, & Paspalas, 2015).
Importantly, theeffectofD1 receptoractivationonneuronal
signal-to-noise ratio appears to follow an inverted-U-shaped
pattern in nonhuman primates and rodents, such that DA
levels that are either too low or too high impair working
memory performance (Vijayraghavan, Wang, Birnbaum,
Williams, & Arnsten, 2007; Zahrt, Taylor, Mathew, &
Arnsten, 1997; Sawaguchi & Goldman-Rakic, 1994).
Although D1-selective agonists are not yet available for
experimental use in healthy humans, to examine the im-
pact of PFC DA levels on cognitive stability researchers
have capitalized on a common single-nucleotide poly-
morphism (SNP) in the gene encoding catechol-O-
methyltransferase (COMT; Lachman et al., 1996), a principal
catabolizer of PFC DA (Käenmäki et al., 2010). Relative to
the COMT Val variant, the Met allele is associated with a
considerable decrease in enzymatic activity (Syvänen,
Tilgmann, Rinne, & Ulmanen, 1997). The resultant accu-
mulation of extracellular DA diffuses from the synapse
where it is hypothesized to preferentially stimulate extra-
synaptic D1 receptors over intrasynaptic D2 receptors
(Bilder, Volavka, Lachman, & Grace, 2004; Winterer &
Weinberger, 2004). Consistent with a D1 receptor mecha-
nism underlying cognitive stability, Met allele carriers are re-
ported to outperform their Val allele counterparts on tasks
that primarily probe the maintenance of memoranda in
working memory (e.g., delayed memory for simple stimuli;
Berryhill, Wiener, Stephens, Lohoff, & Coslett, 2013) and
those that require stabilization of information among
other processes (e.g., n-back; Farrell, Tunbridge, Braeutigam,
& Harrison, 2012; see also Savitz, Solms, & Ramesar, 2006)
but to perform worse on tests that predominantly assess cog-
nitive flexibility (e.g., Cameron, Wallace, Al-Zughoul, Kayser,
& D’Esposito, 2018; Colzato, Waszak, Nieuwenhulis,
Posthuma, & Hommel, 2010). Pharmacological studies using
the brain-penetrant COMT inhibitor tolcapone further
support the inverted-U-shapedmodel of PFCDA:Thebenefits
(or costs) of tolcapone administration on cognitive stability
measures depend on COMT genotype in both healthy
human participants (for a review, see Schacht, 2016) and
transgenic mice (Barkus et al., 2016), such that low-DA Val
allele carriers typically exhibit improved, whereas high-DA
Met allele carriers exhibit diminished, performance on
tasks of cognitive stability following treatment.
D2 receptor expression in the human PFC is considerably
lower than that of the D1 receptor (Hurd, Suzuki, & Sedvall,
2001) and its role in modulating cognitive control is less
clear (Vijayraghavan, Major, & Everling, 2017). In their influ-
ential dual-state neural attractor model, Durstewitz and
Seamans (2008) propose opposing actions of D1 and D2
receptor stimulation based on their relative receptor affini-
ties. Specifically, they argue that, at moderate DA levels, the
PFC enters a D1-dominant state characterized by stable
representations separated by high-energy barriers, whereas
when DA levels are low or high, the PFC transitions to a
D2-dominant state in which shallow and unstable rep-
resentations are separated by low-energy barriers and
therefore susceptible to distraction and spontaneous
switching. However, empirical studies of D2 receptor
function have yielded conflicting results (Vijayraghavan,
Major, & Everling, 2016; Ott et al., 2014). For example,
in contrast to the opponent actions predicted by the
dual-state model, several studies report that D2 receptor
stimulation in nonhuman primate PFC predominantly
influenced the perisaccadic period of an oculomotor work-
ing memory task, pointing to a more circumscribed role for
the receptor in the gating of response signals to the BG,
thalamus, or other motor effector regions (Vijayraghavan
et al., 2016; Wang, Vijayraghavan, & Goldman-Rakic,
2004). Other data, however, suggest that D2 receptor stim-
ulation may influence PFC rule coding and maintenance,
in part through mechanisms that complement those of
D1 receptor stimulation (Ott et al., 2014). Although meth-
odological variability may in part explain these divergent
results, another possibility is that the effects of D2 recep-
tor stimulation on cognitive control processes are me-
diated by individual differences in DA system function
(or proxies for them). Indeed, pharmacological studies
in humans have reported differential effects of D2 family
drugs on task-elicited PFC activation (Cools, Sheridan,
Jacobs, & D’Esposito, 2007) and tasks associated with
frontal lobe function (Kimberg, D’Esposito, & Farah,
1997) as a function of individual differences in trait impul-
sivity and reading span, respectively.
In contrast to the PFC, the striatum is characterized by
dense expression of DA D2 receptors (Hurd et al., 2001).
The dorsal striatum receives topographically organized
PFC inputs and propagates information along two parallel
pathways through the BG circuitry—the putative “direct”
and “indirect” pathways—that ultimately excite or inhibit,
respectively, thalamic projections back to the cortical re-
gions of origin. Release of DA into the striatum from
brainstem dopaminergic neurons differentially modulates
aspects of cell membrane excitability within these two
pathways (Nicola, Surmeier, & Malenka, 2000), facilitating
the “direct” pathway by binding to D1 receptors and in-
hibiting the “indirect” pathway by binding to inhibitory
D2 receptors, the net effect of which is thought to bias
the system toward cognitive flexibility, that is, the activat-
ing or updating of behavioral and cognitive represen-
tations (Frank & O’Reilly, 2006). Striatal DA has been
repeatedly associated with cognitive flexibility in rodents,
primates, and humans (Klanker et al., 2013). For exam-
ple, intrastriatal administration of haloperidol, a D2 re-
ceptor antagonist, reduces behavioral flexibility in rats
(Cools, 1980) and cats ( Jaspers, Schwarz, Sontag, &
Cools, 1984). Similarly, humans with Parkinson disease,
associated with profound loss of DA-producing neurons
in the substantia nigra, exhibit impairments in cognitive
flexibility that are remediated by dopaminergic med-
ication (Costa et al., 2014; Cools, Barker, Sahakian, &
Robbins, 2001, 2003). Strikingly, the degree to which
DA improves cognitive flexibility in Parkinson’s disease
correlates with enhanced striatal activation during
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task-switching (Aarts et al., 2014). Furthermore, in healthy
human adults, performance on tasks of cognitive flexibil-
ity vary with nigrostriatal DA synthesis capacity (Berry,
Shah, & Jagust, 2018) and genetic polymorphisms affect-
ing aspects of DA signaling in the striatum, such as the
ANKK1/Taq1a SNP (Taq1A; Stelzel, Basten, Montag, Reuter,
& Fiebach, 2010). Located 10 kB downstream of the
DRD2 gene (Neville, Johnstone, & Walton, 2004), the
minor A1+ allele of Taq1A is associated with reduced
D2 receptor density (Gluskin & Mickey, 2016) but en-
hanced DA synthesis (Laakso et al., 2005), and its carriers
have been found to outperform A1− homozygotes on
measures of task switching (Stelzel et al., 2010).
As in the PFC, pharmacological modulation of striatal
DA does not uniformly improve cognitive flexibility.
Indeed, whereas studies of healthy adults frequently re-
port no main cognitive benefit of bromocriptine, a DA ag-
onist with strong affinity for D2 receptors (Cameron et al.,
2018; Stelzel, Fiebach, Cools, Tafazoli, & D’Esposito, 2013;
van Schouwenburg et al., 2013; van Holstein et al., 2011;
Cools et al., 2007), significant effects emerge when sam-
ples are stratified according to putative proxies for striatal
DA system function, such as DAT1 genotype (van Holstein
et al., 2011), working memory span (van Holstein et al.,
2011), or trait impulsivity (Cools et al., 2007). In these
studies, bromocriptine typically enhances flexibility only
in individuals posited to have relatively low baseline stria-
tal DA neurotransmission, suggesting that, as in the PFC,
there is a restricted range of striatal DA stimulation within
which cognitive flexibility is optimized.
Despite mounting evidence in the animal literature for
region-, receptor-, and task-specific effects of DA on
cognitive stability and flexibility (Ott & Nieder, 2019),
few human studies to date have directly compared the
differential impact of mechanistically variable DA manip-
ulations on discrete aspects of cognitive control. The
ability to target selective components of the brain’s DA
system is quite limited in human subjects, as most avail-
able drugs bind with variable affinity to multiple recep-
tor types and act diffusely across all brain tissue expressing
these receptors. To overcome this limitation, several strat-
egies have been used, such as the co-administration of
selective agonists and antagonist to isolate effects attribut-
able to specific receptors (e.g., van Holstein et al., 2011;
Frank & O’Reilly, 2006) and the use of multiple drugs with
only partially overlapping mechanisms of action to identify
shared and nonshared effects on behavior (e.g., Cameron
et al., 2018; Bestmann, Ruge, Rothwell, & Galea, 2015;
Bloemendaal et al., 2015; Dodds et al., 2008; Müller,
von Cramon, & Pollmann, 1998). Building on the latter
strategy, we used a within-subject, placebo-controlled de-
sign to contrast the effects of tolcapone (a COMT enzyme
inhibitor) and bromocriptine (a DA receptor agonist with
highest affinity for the D2 receptor) on task maintenance
and switching. In addition to modulating the DA system
through distinct physiological mechanisms, the net influ-
ence of these drugs is likely to be differentially distributed
across brain regions and receptor types. Although COMT
influences the degradation of DA to varying degrees
throughout regions of the brain, including the striatum
and hippocampus (Laatikainen, Sharp, Harrison, &
Tunbridge, 2013), relatively low levels of DA transporter
(DAT) expression in the PFC makes this region more re-
liant on COMT for extracellular DA clearance. Thus, tolca-
pone is expected to exert its effect to a greater extent in
cortex than in striatum (Yavich, Forsberg, Karayiorgou,
Gogos, & Männistö, 2007; Matsumoto et al., 2003). By
contrast, bromocriptine’s actions at D2 receptors are
expected to occur across cortical and subcortical tissues,
though the expression of this receptor type is much
greater in the striatum than in the PFC (Hall et al., 1994;
Camps, Cortés, Gueye, Probst, & Palacios, 1989). To ac-
count for differences in drug effect related to baseline
variation in DA system function, our participants were
stratified according to two SNPs (COMT and Taq1A) asso-
ciated with variation in cortical and striatal DA system
function, respectively. We hypothesized, based on the ev-
idence reviewed above, that, although tolcapone would
improve distractor-resistant task rule maintenance via op-
timization of D1 stimulation in COMT Val homozygotes
(low PFC DA), it may impair such distractor resistance
in Met homozygotes (high PFC DA) potentially by shifting
the balance of D1/D2 stimulation to a D2 state. In con-
trast, bromocriptine was hypothesized to facilitate task
rule switching more generally and, to a greater extent,
in COMT Met (high PFC DA) and Taq1A A1− (low striatal
DA) homozygotes by optimizing D2 receptor stimulation
in PFC and striatum. Finally, we explored the extent to
which drug manipulations exert opposing effects on
facets of cognitive control, consistent with the view that
dopaminergic modulation, even acting across multiple re-
ceptor systems and regions, ultimately serves to bias an
organism toward stability or flexibility.
METHODS
Procedure Overview
Individuals meeting advertised inclusion criteria
were invited to the Helen Wills Neuroscience Institute at
University of California, Berkeley, to provide a saliva sam-
ple for genotyping. Following genotyping, individuals who
met our genotypic criteria (see below) were invited back
to the lab to take part in a health screening and medical
history. During this appointment, participants also com-
pleted a listening span test (Salthouse & Babcock, 1991)
and the Barratt Impulsivity Scale (Patton, Stanford, &
Barratt, 1995) to assess working memory capacity and trait
impulsivity, respectively. Participants meeting medical
criteria were scheduled for three pharmacological study
sessions to be completed on different days. The number
of days separating subsequent sessions ranged from 2 to
86 (median = 7, mean = 10.2, SD = 9.7). At each of the
three sessions, participants were administered a single
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dose of bromocriptine, tolcapone, or placebo, after which
they performed a cognitive task in an MRI scanner.
Neuroimaging results will be described elsewhere.
Although session start times varied between 7 a.m. and
4 p.m., efforts were made to keep start times consistent
across sessions for each participant. All participants gave
written informed consent in accordance with the
Committee for the Protection of Human Subjects at the
University of California, San Francisco, and the University
of California, Berkeley, and were compensated for their
participation.
Participants
Healthy young participants were recruited for genetic
sampling from the University of California, Berkeley,
community and surrounding area using online and print
advertisement. Participants affirmed at the time of ge-
netic sampling that they met initial inclusion criteria:
(1) 18–30 years old, (2) right-handed, (3) current weight
greater than 100 pounds, (4) able to read and speak
English fluently, (5) nondrinker or light drinker (women:
<7 alcoholic drinks/week; men: <8 alcoholic drinks/
week), (8) no recent history of substance abuse, (9) no
history of neurological or psychiatric disorder, (10) not
currently using psychoactive medication or street drugs,
(11) not pregnant, and (12) no contraindications to MRI
(e.g., no claustrophobia, pacemakers, history of sei-
zures, or MRI-incompatible metal in body). Genetically
eligible participants underwent a medical screening with
an on-site physician or nurse practitioner, as well as a
liver function test, to ensure that there were no medical
contraindications to tolcapone and bromocriptine use
and to verify the absence of neurological and psychiatric
history.
Genotyping Overview
Saliva samples were obtained using Oragene collection
kits with stabilizing liquid (DNA Genotek). Genotyping
of COMT (rs4680) and Taq1A (rs1800497) SNP testing
was performed at the UCSF Genomics Core, Vincent J.
Coates Genomics Sequencing Laboratory, and Kashi
Clinical Laboratories using polymerase chain reaction-
based TaqMan technology (Applied Biosystems). Only in-
dividuals who were homozygous for either the Val or Met
allele of the COMT polymorphism were invited to partic-
ipate in the remainder of the study. Consistent with pre-
vious studies (e.g., Stelzel et al., 2010), Taq1A genotypes
were binned according to the presence (“A1+”) or ab-
sence (“A1−”) of any copies of the A1+ minor allele.
To enable us to independently investigate the effects of
each genotype on drug response, participants were se-
lected based on compound COMT/Taq1A genotype, with
roughly equal representation in each of the following
groupings: Met/A1+, Val/A1+, Met/A1−, Val/A1−.
Drugs
During each session, participants received a single oral
dose of bromocriptine (1.25 mg), tolcapone (200 mg),
or placebo. These doses were selected based on their
demonstrated efficacy in eliciting changes in cognitive
performance (e.g., Cameron et al., 2018; Bloemendaal
et al., 2015; Farrell et al., 2012; Gibbs & D’Esposito, 2005).
Bromocriptine reaches peak plasma concentrations between
0.5 and 3.5 hr (mean time to peak = 1.7 hr) after administra-
tion and has an elimination half-life of 3–7 hr (Kvernmo,
Härtter, & Burger, 2006; Price, Debono, Parkes, Marsden,
& Rosenthaler, 1978). Tolcapone reaches peak plasma
concentration, on average, 1.8 hr after oral administration
and has an elimination half-life of about 2 hr ( Jorga,
Fotteler, Heizmann, & Zürcher, 1998). To increase the
probability that participants were near peak plasma drug
concentrations during task performance on both of the
drug days, participants began the task approximately
75 min after drug/placebo administration. The order of
drug administration was under a double blind and coun-
terbalanced across participants (and within genotype
groups). Participants reported side effects (e.g., “drowsy,”
“fatigued”) using visual analogue scales at the beginning
of each session (“baseline”), before task performance,
and immediately following task performance. Given con-
cerns that drug-related changes in drowsiness or fatigue
may influence task performance, we computed changes
in “drowsy” and “fatigued” scores from baseline to pre-
scan (“prescan scores”) and from baseline to postscan
(“postscan scores”) for each of the three sessions and in-
cluded these variables in control iterations of relevant
statistical models.
At the conclusion of each session, participants were
asked to guess whether they had received a placebo or
drug on that day. As a group, participants demonstrated
no better than chance-level accuracy in their guesses, and
rates of “drug” vs. “placebo” guesses did not differ signif-
icantly across the three sessions, χ2(2) = 3.2, p = .2 (ex-
cludes four omitted responses). Following placebo, 56%
of participants believed they had been given one of the
dopaminergic drugs, whereas 51% and 42% believed this
to be the case following bromocriptine and tolcapone
administration, respectively.
Cognitive Paradigm
We adapted the task-switching paradigm developed by
Armbruster, Ueltzhöffer, Basten, and Fiebach (2012; see
Figure 1). On each trial, participants were required to re-
spond quickly to digits between 1 and 9 (excluding 5)
that appeared in different shades of gray against a black
background. On 82% of trials, a single digit appeared
above a central fixation cross at a constant, medium gray
value (i.e., 127). For these “ongoing task” trials, par-
ticipants performed an operation on the digit and re-
sponded by pressing the index finger of either their left
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or right hand. Participants were trained to make either
odd/even or low/high decisions on these ongoing task
digits; task assignment (“version”) was counterbalanced
across individuals within genotype group. On the remain-
ing 18% of trials, two digits appeared on the screen simul-
taneously, one above and one below the fixation cross.
The relative brightness of the upper and lower digits var-
ied and encoded a task cue. When the upper digit was
brighter (gray value ranging from 169 to 195; one third
of non-ongoing task trials, 6% of total trials), participants
were instructed to ignore the lower digit (gray value =
[255 − value of upper digit]) and continue to apply the
ongoing task rule to the upper digit (“distractor trials”).
When the lower digit was brighter (gray value ranging
from 169 to 195; one third of non-ongoing task trials,
6% of total trials), participants were signaled to switch at-
tention to the lower digit (gray value = [255 − value of
upper digit]) and to apply the alternate task rule to it
(“switch trials”). On the final third of these trials (6% of
total trials), the difference in brightness between the up-
per and lower digits was reduced (“ambiguous trials”);
for these trials, the gray value of the upper digit remained
set at 127 and the value of the lower digit ranged from
117 to 137. As participants were only trained to respond
to the brighter of the two digits, this trial type was de-
signed to assess the extent to which participants are prone
to switching under ambiguous conditions (Armbruster
et al., 2012). In the original paradigm, participants were
required to switch hands when they switched tasks; in
the current version, we had participants instead switch
to responding with the middle fingers of the left and right
hand to minimize the biasing of behavior as a function of
hemispheric dominance. Participants performed a total of
990 trials distributed across three blocks with brief
interposed breaks. Individual switch, distractor, and am-
biguous trials were pseudorandomly interspersed among
runs of three to six contiguous ongoing task trials. Digits
remained on the screen for 900 msec, but responses were
registered for the duration of each 2000-msec trial. There
were no additional intertrial intervals. Before testing on
each of the 3 days, participants underwent task training,
the final stage of which required them to respond correctly
to at least five of the previous seven switch/distractor trials
to proceed to testing. To reduce the extent to which par-
ticipants developed explicit response strategies, ambigu-
ous trials were only presented during the final stage of
training when performance feedback was not provided.
Data Preparation and Analysis
To reduce the inclusion of nonspecific session or drug
effects in our analyses, we did not include data from in-
dividual task blocks for which ongoing task response rate
was lower than 60% or for which accuracy on ongoing,
distractor, or switch trials was less than “chance,” defined
as 50% for ongoing trials and 25% for distracter and
switch trials based on the number of potential button
presses at play (2 vs. 4) during these trial types. This pro-
cedure resulted in the exclusion of 13 total task blocks
from eight unique participants (five placebo, six bromo-
criptine, two tolcapone). We further excluded from analy-
sis the first trial of each block, as well as trials immediately
following inaccurate responses and trials immediately fol-
lowing distractor, switch, or ambiguous trials, to reduce
possible “contamination” from other cognitive control pro-
cesses (Armbruster-Genç, Ueltzhöffer, & Fiebach, 2016).
Together, these procedures excluded 25.5% of trials. For
analysis of RT data, we additionally excluded individual
Figure 1. Schematic of task-switching paradigm. Participants applied their dominant task rule (pictured: parity rule) when operating on digits
appearing above the central crosshair and the alternate rule (pictured: magnitude rule) when operating on digits appearing below it. When two
numbers appeared simultaneously in both locations, participants were instructed to operate on whichever of the upper (“distractor trial”) or
lower (“switch trial”) digits was brightest. Trials on which the difference in brightness between the two digits was reduced (“ambiguous trials”)
allowed for the examination of spontaneous switch tendency in the absence of explicit cues. Responses to upper and lower digits were made with
index and middle fingers, respectively.
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trials for which RT was greater or less than 3 SDs from the
subject-level mean for a given trial type and drug, increas-
ing the total number of excluded trials to 26.5%. To better
satisfy data normality assumptions associated with linear
models, mean RTs were log-transformed, and mean per-
cent error scores were arcsine-square root transformed
before analysis.
Mean RTs from accurate trials and percent error scores
were analyzed with separate linear mixed-effects models
implemented with the “lme4” (Bates, Mächler, Bolker,
& Walker, 2015) and “afex” (Singmann, Bolker, Westfall,
& Aust, 2018) libraries in R (version 3.5.1). Models
were constructed to test the primary hypothesis that
bromocriptine and tolcapone (relative to placebo) admin-
istration would differentially influence switch and distrac-
tor (relative to ongoing) trial performance and, further,
that Taq1A and COMT genotypes might mediate these
effects. Additional covariates (i.e., session number and
ongoing task version) were included in the model to ac-
count for potential confounds at the level of baseline task
performance (i.e., ongoing task performance on placebo).
Thus, fixed effect predictors included the within-subject
variables trial type (treatment-coded: ongoing [reference
level], switch, distractor), drug (treatment-coded: placebo
[reference level], bromocriptine, tolcapone), and session
number (centered on session 1), as well as the between-
subject variables ongoing task version (deviation-coded:
magnitude, parity), COMT genotype (deviation-coded:
Val, Met), and Taq1A genotype (deviation-coded: A1−,
A1+). In addition, we included a covariate represent-
ing the task block number (within session; centered
on Run 1) to determine whether effects of interest varied
linearly over the course of the session, potentially due to
condition-specific fatigue effects. Our primary terms of
interest—interactions between trial type, drug, and
genotype—were included separately for each of the two
SNPs. Finally, the four-way interactions of trial type, drug,
genotype (separately for the two SNPs), and task block
number were included to further qualify our interactions
of interest. Among these variables, all lower order inter-
actions were included in the model to facilitate inter-
pretability. A maximal random effects structure was
used to minimize Type I error (Barr, Levy, Scheepers,
& Tily, 2013); thus, random effects included the intercept
of subject, as well as the slopes of drug, trial type, and
block number within subject. F tests were computed
for fixed effects using the Satterthwaite method for
approximating degrees of freedom. Follow-up z tests
contrasting distractor versus ongoing trial estimates (“dis-
tractor costs”) and switch versus ongoing trial estimates
(“switch costs”) were corrected for multiple comparisons
using the false discovery rate method implemented in
the “emmeans” package (Lenth, 2018). For interpret-
ability, we present estimated marginal effects and
standard errors that have been back-transformed to
the original scale (e.g., milliseconds, % error) in text
and figures.
Because errors of commission on switch trials may
reflect distinct types of failures of cognitive control, we
divided such errors into two categories to better charac-
terize the effects of drug and genotype: (1) switch trials
on which participants continued to perform the ongoing
task (“failures to switch”) and (2) switch trials on which
participants switched tasks (as evidenced by use of the
middle fingers to respond) but made a response error
(“execution error”). “Failures to switch” and “execution
error” metrics were computed as the percentage of this
type of error out of all (nonomitted) switch trial responses,
arcsine-square root transformed to approximate normal-
ity, and analyzed with linear mixed-effects models as de-
scribed above. Because of the relatively small number of
exemplars per session, error rates were aggregated
across task blocks for these analyses.
Next, we computed the proportion of ambiguous trials
(excluding trials with omitted responses) that partici-
pants treated as task switches (as evidenced by their
use of middle fingers to respond). Here, we report on
the analysis restricted to accurate trials, though the pat-
tern of results is unchanged when inaccurate trials are in-
cluded. In this context, an accurate response reflects the
correct response based on the decision to either main-
tain the ongoing task or to switch tasks, regardless of
the relative luminance of the stimuli. This metric was
arcsine-square root transformed to approximate nor-
mality and analyzed with a linear mixed-effects model.
Previous work suggests that DA may influence visual pro-
cessing (Brandies & Yehuda, 2008); given that the lumi-
nance difference between the upper and lower digits
varied in magnitude and direction across ambiguous tri-
als, we conducted an additional control analysis to ensure
that any drug effects on switching rates were not driven
by changes in the ability to perceive these subtle dif-
ferences in luminance. Accurate trial-wise (n = 11,004)
responses (switch, nonswitch) were analyzed using a bi-
nomial generalized linear mixed-effects model with fixed
effect predictors of drug, session number, ongoing task
version, COMT genotype, Taq1A genotype, and lumi-
nance difference (−10≤ x ≤10, where differences are
computed relative to the reference gray value of 127, as
noted above). For this analysis, the interactions of inter-
est were among the factors drug, genotype, and lumi-
nance difference. The maximal random effects structure
employed here included the intercept of subject and the
slopes of drug, luminance difference, and their interac-
tion within subject. Likelihood ratio tests were used to
determine statistical significance. The bromocriptine ses-
sion for one additional participant (Met/A1−) was ex-
cluded from analyses of ambiguous trial behavior due
to unusually low performance on this particular trial type
(>75% error rate).
Finally, in an exploratory set of analyses, we examined
the extent to which dopaminergic drugs exert opposing
effects on measures of cognitive stability and flexibility.
We first computed Spearman’s correlations among drug
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Table 1. Raw Task Performance by Genotype, Drug, and Trial Type
Genotype N Drug















% Switch Rate (SD)/
% Accurate Only (SD)
Taq1A A1+ 41 Placebo 574 (109) 6.2 (4.5) 695 (140) 9.2 (7.1) 955 (202) 19.1 (12.1) 4.7 (4.6) 22.5 (18.9)/21.4 (19.0)
41 Bromocriptine 574 (95) 6.8 (4.6) 709 (135) 11.0 (7.7) 972 (228) 20.1 (12.9) 5.9 (8.0) 25.2 (21.1)/22.9 (20.9)
41 Tolcapone 568 (80) 7.3 (5.5) 706 (107) 11.0 (6.9) 961 (194) 18.7 (13.2) 4.7 (4.4) 23.6 (20.5)/22.3 (21.2)
A1− 39 Placebo 568 (100) 5.3 (4.2) 727 (174) 10.0 (6.8) 920 (177) 17.8 (13.6) 5.4 (5.5) 30.0 (22.6)/28.3 (23.9)
39 Bromocriptine 568 (99) 5.3 (4.3) 730 (155) 9.4 (6.9) 934 (179) 14.3 (11.0) 3.5 (5.1) 28.5 (19.9)/27.0 (20.5)
39 Tolcapone 575 (100) 5.1 (4.3) 737 (157) 9.3 (5.8) 926 (161) 16.3 (11.7) 4.6 (5.1) 30.1 (20.0)/27.9 (21.1)
COMT VAL 41 Placebo 560 (119) 5.9 (4.7) 699 (178) 9.0 (6.9) 928 (209) 17.5 (10.7) 5.0 (5.3) 25.1 (19.0)/23.9 (19.5)
41 Bromocriptine 556 (108) 5.8 (4.4) 696 (165) 9.8 (7.6) 945 (224) 17.4 (12.5) 4.3 (5.1) 21.4 (17.1)/19.3 (15.8)
41 Tolcapone 556 (105) 5.6 (4.5) 690 (147) 9.4 (6.3) 928 (198) 16.8 (12.2) 4.8 (5.3) 24.2 (19.4)/22.7 (19.8)
MET 39 Placebo 584 (86) 5.6 (4.0) 723 (134) 10.2 (7.0) 948 (170) 19.6 (14.8) 5.1 (4.8) 27.3 (23.1)/25.6 (23.9)
39 Bromocriptine 587 (80) 6.3 (4.6) 743 (117) 10.7 (7.1) 963 (186) 17.2 (12.2) 5.1 (8.3) 32.6 (22.4)/30.9 (23.7)























effects for distractor and switch RT and accuracy (error
rate) costs (e.g., Δ distractor RT cost: drug distractor RT
cost − placebo distractor RT cost), separately for bromo-
criptine and tolcapone effects. Given our pattern of re-
sults (described below), we used principal components
analyses (PCA) to reveal secondary structures in the data.
PCA with varimax rotation was conducted separately for
bromocriptine- and tolcapone-related changes, with the
following metrics: Δ distractor RT cost, Δ distractor ac-
curacy cost, Δ switch RT cost, and Δ switch accuracy cost.
Metrics were mean-centered and scaled to unit variance
before analysis. To compare the structure of compo-
nents between the two drug conditions, Procrustes ro-
tation of the tolcapone component matrix to match the
bromocriptine matrix was followed by computation of
Tucker’s coefficient of congruence, a cosine similarity
measure (Lorenzo-Seva Δ ten Berge, 2006). PCA analysis
was conducted using the R psych library (Revelle, 2018).
RESULTS
Participant Data
Our sample included 80 participants belonging to the fol-
lowing COMT/Taq1A genotype groups: Met/A1+ (n= 20,
10 female, age [mean ± SD] = 20.6 ± 2.4 years), Val/
A1+ (n = 21, 15 female, age = 21.0 ± 1.7 years), Met/
A1− (n = 19, 15 female, age = 21.8 ± 3.6 years), and
Val/A1− (n = 20, 11 female, age = 21.3 ± 2.2 years).
For illustrative purposes, untransformed mean RTs, error
rates, and switch rates by genotype group are provided in
Table 1.
Reaction Time
All F values are presented in Table 2, and estimated mean
RT scores are presented in Figure 3. Consistent with pre-
vious results using this task (Armbruster et al., 2012), the
analysis of RT yielded a simple effect of Trial Type, F(2,
93.26) = 479.74, p< .0001, such that costs were incurred
for both switch (estimated marginal effect = 355 msec;
z=28.75, p< .0001) and distractor (130msec; z=17.57,
p< .0001) trials relative to ongoing trials on placebo. We
also observed effects of Study Session, F(1, 140.1) =
50.97, p < .0001, and Task Block, F(1, 75.29) = 63.14,
p < .0001; in both cases, ongoing task responses were
faster with each subsequent session or task block (within
session).
There were no effects of Drug, F(2, 113.78) = 2.36,
p = .1; COMT Genotype, F(1, 72.99) = 2.26, p = .14;
or Taq1A Genotype, F(1, 72.99) = 0, p = .99, on ongoing
task RT, nor a significant Drug × Trial Type interaction,
F(4, 1605.2) = 1.77, p = .13. However, we identified a
three-way interaction of Drug, Trial Type, and COMT
Genotype on RT, F(4, 1605.21) = 2.63, p = .03; tolca-
pone increased distractor cost (i.e., distractor RT vs. on-
going task RT) in Met homozygotes (estimated marginal
effect =+27msec, z=2.96, p= .01; Figure 2, top) but not
in Val homozygotes (+1 msec, z = 0.1, p = .92).
No comparable Tolcapone × COMT genotype effect
was found for switch cost, nor were there significant
Bromocriptine × COMT genotype effects for either dis-
tractor or switch cost (all |z|s ≤ 2, ps > .1).
Though not of central focus to the current study, our
RT model indicated that dopaminergic drugs may influ-
ence the dynamics of performance over time. We include
a description of these results here for completeness, as
well as to demonstrate that such temporal dynamics do
not fully account for the Drug × Trial type × COMT ge-
notype interaction reported above. Specifically, a Drug ×
Task Block interaction, F(2, 1625.72) = 3.33, p = .04,
revealed that, relative to placebo, the two drugs differed
in their modulation of ongoing task RT change across
blocks; whereas bromocriptine tended to reduce the
negative slope of ongoing task RT change across blocks
Table 2. ANOVA Table for Mixed Model of RT
Effect df F p
Taq1A 1, 72.99 0.00 .99
COMT 1, 72.99 2.26 .14
Drug 2, 113.78 2.36 .10
Type 2, 93.26 479.74 <.0001
Block 1, 75.29 63.14 <.0001
Session 1, 140.10 50.97 <.0001
Version 1, 75.17 2.89 .09
Taq1A × Drug 2, 113.81 0.07 .93
COMT × Drug 2, 113.82 4.81 .01
Taq1A × Type 2, 93.27 1.95 .15
COMT × Type 2, 93.28 0.84 .44
Drug × Type 4, 1605.20 1.77 .13
Taq1A × Block 1, 75.31 0.00 .99
COMT × Block 1, 75.31 0.03 .86
Drug × Block 2, 1625.72 3.33 .04
Type × Block 2, 1605.51 55.91 <.0001
Taq1A × Drug × Type 4, 1605.20 0.67 .61
COMT × Drug × Type 4, 1605.21 2.63 .03
Taq1A × Drug × Block 2, 1625.93 0.22 .80
COMT × Drug × Block 2, 1626.13 8.21 .0003
Taq1A × Type × Block 2, 1605.52 0.15 .86
COMT × Type × Block 2, 1605.48 0.05 .95
Drug × Type × Block 4, 1605.11 0.76 .55
Taq1A × Drug × Type × Block 4, 1605.11 0.43 .79
COMT × Drug × Type × Block 4, 1605.13 1.56 .18
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(estimated marginal trend =+2.73 msec, z= 0.65, p= .51;
less improvement over time), tolcapone tended to in-
crease it (−5.07 msec, z = −1.21, p = .46; greater im-
provement over time), though neither drug effect on its
own reached statistical significance. This interaction was
qualified by a three-way interaction of Drug, Task Block,
and COMT Genotype, F(2, 1626.13) = 8.21, p = .0003,
such that a significant difference in the effects of bromo-
criptine and tolcapone on ongoing task RT slope was
present in COMT Met (z = 2.03, p = .04) but not in Val
(z= 0.60, p= .55) participants. Importantly, the four-way
interaction of Drug, Task Block, COMTGenotype, and Trial
Type was insignificant, F(4, 1605.13) = 1.56, p = .18, indi-
cating that the interaction of drug, trial type, and COMT
genotype (reported above) was likely not driven by incre-
mental deterioration in attention or other nonspecific
drug-related changes over time. Similarly, the three-way
interaction of COMT Genotype, Drug, and Trial Type re-
mained significant when either prescan, F(4, 1597.69) =
2.47, p = .04, or postscan, F(4, 1597.24) = 2.61, p = .03,
delta scores for both fatigue and drowsiness were in-
cluded as covariates in the model.
Error Rates
All F values are presented in Table 3, and estimated mean
error rates are presented in Figures 2 and 3. As expected,
we obtained a simple effect of trial type on error rates,
F(2, 191.75) = 62.4, p < .0001, such that relative to on-
going trials, more errors were made on distractor (esti-
mated marginal effect = +1.8%; z = 3.23, p = .001)
and switch (+10.8%; z = 10.35, p < .0001) trials on pla-
cebo. We found no effects of Drug or Genotype, nor any
significant interactions among Drug, Genotype, and Trial
Type (all Fs ≤ 2.3, ps ≥ 0.1; Figure 2, bottom).
Next, we investigated the effects of drug and geno-
type on a particular category of errors: those in which
Figure 2. Estimated RT (top) and accuracy (ACC; bottom) costs by trial type for each drug condition (placebo, bromocriptine, tolcapone) and
genotype (Taq1A, COMT). Estimates are back-transformed and reflect differences in RT or error rate from the ongoing task condition. Error
bars represent back-transformed standard errors estimated from the corresponding mixed models with the “emmeans” package in R. *p < .05.
Table 3. ANOVA Table for Mixed Model of Error Rates
Effect df F p
Taq1A 1, 70.70 2.64 .11
COMT 1, 70.71 1.77 .19
Drug 2, 198.65 0.13 .88
Type 2, 191.75 62.40 <.0001
Block 1, 73.02 0.06 .81
Session 1, 152.49 3.83 .05
Version 1, 76.41 4.24 .04
Taq1A × Drug 2, 198.71 2.28 .11
COMT × Drug 2, 198.74 0.65 .52
Taq1A × Type 2, 191.79 0.82 .44
COMT × Type 2, 191.82 1.27 .28
Drug × Type 4, 1678.03 0.71 .59
Taq1A × Block 1, 73.05 0.59 .45
COMT × Block 1, 73.04 2.46 .12
Drug × Block 2, 1700.56 0.16 .85
Type × Block 2, 1678.60 10.95 <.0001
Taq1A × Drug × Type 4, 1678.03 0.89 .47
COMT × Drug × Type 4, 1678.05 0.65 .63
Taq1A × Drug × Block 2, 1700.75 0.86 .43
COMT × Drug × Block 2, 1700.89 2.96 .05
Taq1A × Type × Block 2, 1678.63 0.06 .94
COMT × Type × Block 2, 1678.54 0.59 .56
Drug × Type × Block 4, 1677.91 0.62 .65
Taq1A × Drug × Type × Block 4, 1677.91 0.43 .79
COMT × Drug × Type × Block 4, 1677.95 0.58 .68
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participants responded to a switch cue as if they were
performing the ongoing task or “failures to switch.”
Such errors, comprising 0–100% of all switch trial errors
(range: 0–14 instances per session), are hypothesized to
result from relatively reduced striatal activation of D2 re-
ceptors and therefore to be susceptible to remediation by
D2 agonists. Analysis of this specific error rate revealed no
effects of Drug, F(2, 153) = 0.90, COMT Genotype, F(1, 76)
= 0.15, or Taq1A Genotype, F(1, 76) = 0.46, all ps > .1, but
a significant interaction of Drug and Taq1A Genotype, F(2,
153) = 4.64, p= .01. Relative to placebo, bromocriptine re-
duced failures to switch in A1− homozygotes (estimated
marginal effect = −2.3%; z = −3.02, p = .005), but not
in A1+ carriers (+1%; z = 1.18, p > .1; Figure 3). There
was no effect of tolcapone on switch failures in either
Taq1A group (A1−: −1%, z = −1.16, p > .1; A1+:
+0.1%, z = 0.17, p > .1) nor an interaction of Drug ×
COMT Genotype on failure to switch, F(2, 153) = 0.1, p
= .9. By contrast, when considering switch “execution er-
rors,” the propor- tion of switch trials on which participants
correctly switched response set but still made an incorrect
button response, there were effects of session number, F
(1, 153) = 18.94, p < .0001, and ongoing task version, F
(1, 76) = 13.17, p = .0005, but no effect of Drug,
Genotype, or Drug × Genotype interaction (all Fs <
1.65, ps > .1).
In summary, our RT results suggest that tolcapone
selectively influenced cognitive stability and only in indi-
viduals with putatively high baseline PFC DA levels. By
contrast, our analysis of error rates demonstrated that
bromocriptine reduces a particular class of switch trial er-
rors in Taq1A A1− homozygotes, but not in A1+ carriers.
Tolcapone did not alter error rates, either across the sam-
ple or in interaction with either genotype. This pattern
suggests that bromocriptine may interact with baseline
striatal DA system function (or more globally with D2 re-
ceptor signaling) to facilitate cognitive flexibility.
Spontaneous Switch Rate
Across sessions, the average (untransformed) switch pro-
portion among accurate ambiguous trials was 24.9%
(range: 0–100%), considerably lower than the 54.8% orig-
inally reported by Armbruster et al. (2012). However, in
the prior study, only a single block of data was collected.
Considering just the first block of the first session in the
current study, irrespective of drug condition, we obtain
an average accurate switch proportion (41.5%) much
closer to their estimate, indicating that the ambiguous
condition produced similar sample-level results as it
has in the past. This finding also highlights the fact that,
in the current context, decisions regarding which task to
perform vary with exposure to ambiguous trials. Indeed,




ambiguous trials by COMT
genotype and drug (placebo,
bromocriptine, tolcapone).
Higher values indicate that
a greater proportion of
ambiguous trials were treated
as switch trials, as indicated by
the use of middle fingers for
responding. Means and error bars
reflect back-transformed estimates
from the corresponding mixed
model with the emmeanspackage
in R. *p< .05.
Figure 3. Estimated switch trial errors (percentage of total switch trial
responses) by error type, Taq1A genotype, and drug (placebo, bromocriptine,
tolcapone). Errors of commission were classified according to whether
participants switched to the correct response set (middle fingers) but
pressed the wrong button (“execution errors”) or failed to switch to the
correct response set (“failures to switch”). Error bars represent
back-transformed standard errors estimated from the corresponding
mixed models with the “emmeans” package in R. *p < .01.
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yielded a main effect of Session, F(1, 152.19) = 15.49,
p = .001, on transformed switch rates, such that, on aver-
age, switch proportion decreased with each subsequent
session.
Despite this systematic variation in switch rates across ses-
sions, we obtained a significant Drug × COMT Genotype
interaction, F(2, 152.13) = 5.62, p = .004 (Figure 4) that
was driven by an increase in switch proportion on bromo-
criptine (relative to placebo) for Met (estimated marginal ef-
fect = +7.6%; z = 2.66, p= .016) but not Val (−4.9%; z=
−2, p= .09) homozygotes. No other factors were predictors
of spontaneous switch rate (all Fs < 2, ps > .1). Including
both accurate and inaccurate ambiguous trials in the cal-
culation of switch proportion did not change the overall pat-
tern of significant results. Our control analysis (see Table 4)
indicated that luminance differences linearly influenced
trial-wise decisions to either switch tasks or repeat the on-
going task, χ2(1) = 36.97, p< .0001; however, we found no
evidence for interactions of Luminance × Drug, χ2(2) =
4.13, p = .13; Luminance × COMT Genotype, χ2(1) = 0.01,
p= .91; Luminance×Taq1AGenotype,χ2(1)=1.28, p= .26;
Luminance × Drug × COMT Genotype, χ2(2) = .05,
p = .97; or Luminance × Drug × Taq1A Genotype,
χ2(2) = 1.39, p = .5. Importantly, the interactive effect
of Drug and COMT Genotype remained significant with lu-
minance included in the model, χ2(2) = 13.18, p = .001.
In summary, our exploration of spontaneous switching
behavior revealed that bromocriptine induced a bias to-
ward greater spontaneous switching in COMT Met, but
not Val, homozygotes that were unrelated to altered
visual perception but did not interact with Taq1A geno-
type to predict drug-related changes in spontaneous
switching, contrasting with the previous finding of
bromocriptine-modulated change in cued task switching
(see Error Rates section).
Additional Explanatory Variables
Trait-like measures of working memory span and impul-
sivity have been found to moderate the effects of dopa-
minergic manipulations (e.g., Cools et al., 2007). Thus,
we examined the extent to which genotypic differences
in our drug effects could be explained by variability in
these more proximal phenotypes. Neither baseline work-
ing memory (listening span score), t(77) = 0.46, p = .64
(Val: mean = 3.0, SD = 0.8; Met: mean = 2.9, SD = 0.9),
nor trait impulsivity (Barrett Impulsivity Scale score),
t(78) = 1.04, p = .30 (Val: mean = 56.2, SD = 8.1; Met:
mean = 58.3, SD = 9.4), varied by COMT genotype.
Furthermore, COMT genotype was the sole predictor of
tolcapone-related change in (log-transformed) distractor
RT cost (b= 0.022, t= 2.11, p= .038) when all three mea-
sures were entered as predictors in a linear regression
model. Similar results were obtained for the effect of
COMT genotype on bromocriptine-related change in
(arcsin-transformed) spontaneous switch rate (b = 0.07,
t = 3.06, p = .003).
Listening span score did not differ between Taq1A ge-
notypes, t(77) = 0.08, p = .9 (A1−: mean = 3, SD = 0.9;
A1+: mean = 3, SD = 0.9). However, impulsivity score
was marginally associated with Taq1A genotype, t(78) =
1.84, p = .07. Consistent with previous work (Eisenberg
et al., 2007), A1+ carriers were more impulsive (mean =
59.0, SD = 8.25) than were A1− homozygotes (mean =
55.4, SD = 9.04). As the sole factor in a regression model,
impulsivity score predicted bromocriptine-related change
in (arcsin-transformed) switch failure proportion (b = 0.03,
t = 2.04, p = .045). However, adding Taq1A genotype to
the model fully reduced this contribution to insignificance
(impulsivity: t= 1.51, p= .14; Taq1A: t= 2.82, p= .006),
suggesting that Taq1A genotype likely gives rise to
concurrent variation in impulsivity score and behavioral
drug effect.
Interactions among Facets of Cognitive Control
Across the sample, correlations among drug effects did
not provide evidence for antagonistic effects of dopa-
minergic drugs on cognitive stability and cognitive flexi-
bility. Changes (from placebo) in distractor RT cost and
switch RT cost were uncorrelated for both drugs (bromo-
criptine: ρ = −0.1, p = .4; tolcapone: ρ = 0.1, p = .3).
On the other hand, Δ distractor accuracy cost and Δ
switch accuracy cost were positively correlated for both
bromocriptine (ρ = 0.25, p = .03) and tolcapone (ρ = 0.42,
p = .0001). This result indicates that indices of task
accuracy may generally track together. However, to inves-
tigate whether there is additional structure in the drug ef-
fects suggestive of a subtler anticorrelation pattern among
task components, we conducted PCA on the set of drug-
Table 4. ANOVA Table for Generalized Mixed Model of
Spontaneous Switching
Effect df χ2 p
Taq1A 1 1.84 .17
COMT 1 0.00 .98
Drug 2 0.27 .87
Luminance 1 36.97 <.0001
Session 1 12.70 .0004
Version 1 1.13 .29
Taq1A × Drug 2 1.07 .58
COMT × Drug 2 13.18 .001
Taq1A × Luminance 1 1.28 .26
COMT × Luminance 1 0.01 .91
Drug × Luminance 2 4.13 .13
Taq1A × Drug × Luminance 2 1.39 .50
COMT × Drug × Luminance 2 0.05 .97
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related change scores separately for bromocriptine and
tolcapone. PCA of bromocriptine-related effects yielded
two factors with eigenvalues greater than 1 (Table 5,
top). The first component accounted for 34% of the vari-
ance and was characterized by unidirectional loadings of
distractor and switch accuracy change, consistent with the
obtained positive correlation between these two metrics.
The second component accounted for 27% of the vari-
ance and was characterized by loadings of Δ distractor
and switch RT cost in opposing directions. PCA of
tolcapone-related effects yielded a single component with
an eigenvalue greater than 1 that accounted for 41% of the
variance. Nonetheless, we retained the second com-
ponent (eigenvalue = 0.93; 27% of variance) to facilitate
comparison with bromocriptine-related changes (Table 5,
middle). Both distractor-related metrics and Δ switch ac-
curacy cost loaded unidirectionally onto the first compo-
nent, whereas Δ switch RT cost loaded highly on the
second component with some contribution from Δ switch
accuracy cost. Procrustes rotation of the tolcapone com-
ponents to match the bromocriptine components re-
vealed greater similarity of the second components: For
tolcapone, strong loading of Δ switch RT cost was met
by opposing, albeit considerably weaker, loading of
distractor RT and accuracy costs (Table 5, bottom).
Tucker’s congruence coefficient was 0.94 and 0.88 for
Components 1 and 2, respectively. These values indicate
more evidence for concordance between drugs on the
first component, although both fall within the [0.85–
0.94] range indicative of “fair similarity” (Lorenzo-Seva &
ten Berge, 2006). The lower congruence coefficient for
the second component, combined with the relatively
low eigenvalue for the tolcapone data, suggests that there
is more evidence for opposing drug-elicited effects on
cognitive stability and flexibility with bromocriptine than
with tolcapone. Of note, scores on the second compo-
nent did not vary by COMT or Taq1A genotype for either
bromocriptine or tolcapone (all |t|s < 1.3, ps > .1).
DISCUSSION
Few studies to date have directly compared the effects of
mechanistically divergent dopaminergic drugs on distinct
facets of cognitive control within the same healthy human
sample. Here, we assessed the relative influences of tolca-
pone, an inhibitor of the catecholamine-catabolizing en-
zyme COMT, and bromocriptine, a monoamine agonist
with strong affinity for the DA D2 receptor, on cognitive
stability (i.e., the ability to maintain task and response rule
information in the presence of salient and directly com-
peting distractors), cognitive flexibility (i.e., the ability to
quickly respond to changing environmental cues by reallo-
cating attention and remapping response contingencies),
and their relative anticorrelation. Exploiting putative base-
line dependence of DA effects on human cognitive per-
formance, we attempted to better characterize drug
effects by examining their interaction with known genetic
polymorphisms affecting PFC and striatal DA system
function. We observed a dissociation in the influence of
the two drugs on domains of cognitive control, such that
tolcapone impacted distractor resistance whereas bro-
mocriptine promoted both spontaneous and cued task
switching. In both cases, drug effects were found only in
genotypically defined subgroups, consistent with the pre-
viously documented baseline dependence of DA treat-
ment responses (Cools & D’Esposito, 2011). Together,
our results support the view that the cognitive effects of
DA drugs vary not only as a function of the DA system
component upon which they act, but also on subtle dif-
ferences in task demands and context.
Tolcapone Perturbs Distractor Resistance in
High-DA Participants
Based on current models of the role of DA in stabilizing
PFC representations, we hypothesized that tolcapone
would differentially impact distractor resistance in COMT
Met and Val homozygotes, enhancing performance on dis-
tractor trials in putatively low-DA Val homozygotes and
Table 5. Component (C) Loadings from Principal Component
Analysis of Bromocriptine (Top) and Tolcapone (Middle,
Bottom) Drug Effects
Bromocriptine C1 C2
Δ distractor acc cost 0.78
Δ distractor RT cost 0.74
Δ switch acc cost 0.77
Δ switch RT cost −0.73
Tolcapone C1 C2
Δ distractor acc cost 0.88
Δ distractor RT cost 0.74
Δ switch acc cost 0.57 0.39
Δ switch RT cost 0.96
Tolcapone (Rotated) C10 C20
Δ distractor acc cost 0.79 0.38
Δ distractor RT cost 0.65 0.35
Δ switch acc cost 0.69
Δ switch RT cost 0.50 −0.82
For each analysis, four input variables included drug-related change
scores (i.e., drug − placebo) for distractor and switch costs (i.e.,
distractor/switch performance − ongoing task performance). Bottom
panel depicts tolcapone component loadings after Procrustes rota-
tion was used to best match bromocriptine components. Loadings are
thresholded at |0.3|.
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worsening it in high-DA Met homozygotes. Although tolca-
pone did not demonstrably improve cognitive stability in
Val homozygotes in the current study, we found that tol-
capone induced response slowing on distractor (but not
switch) trials in Met homozygotes. This latter finding is
consistent with reports of performance impairment follow-
ing tolcapone administration (or “overdosing”) in Met
homozygotes across a range of paradigms that require
cognitive stability, including the n-back task (Farrell
et al., 2012; Giakoumaki, Roussos, & Bitsios, 2008) and
the intradimensional set-shifting task (Apud et al., 2007),
which assesses the extent to which individuals can form
and stably maintain attentional sets, and on tests of pre-
pulse inhibition, a metric thought to reflect the filtering
out of irrelevant incoming sensory information at early
stages of processing (Giakoumaki et al., 2008). Similarly,
in mice expressing humanized Val or Met alleles, tolca-
pone induces improvement in Val/Val mice but perfor-
mance decrements in Met/Met mice on a test of delayed
spatial working memory (Risbrough, Ji, Hauger, & Zhou,
2014).
By inhibiting the enzyme COMT, tolcapone increases
the accumulation of extracellular DA but does not selec-
tively target D1 or D2 receptors. Given the relative pau-
city of DA transporters in the PFC, it is suspected that
accumulating cortical DA tends to diffuse from the synap-
tic cleft to influence extrasynaptic D1 receptor binding
(Slifstein et al., 2008; Bilder et al., 2004). Thus, a supraop-
timal level of D1 receptor stimulation may be a primary
contributor to poorer performance in the high baseline
DA group. The mechanisms underlying the deleterious
effects of D1 overdose on cognitive performance are still
being investigated; however, it has been argued that, al-
though PFC D1 receptor stimulation within the optimal
range stabilizes and tunes sensory or rule representa-
tions in part by enhancing lateral inhibition and opening
hyperpolarization-activated cyclic nucleotide-gated chan-
nels, at higher levels of stimulation these inhibitory pro-
cesses may suppress neuronal firing more globally, including
responses to currently relevant rules or preferred stimu-
lus features (Arnsten et al., 2015; Vijayraghavan et al.,
2007). By extension, D1 overdose in Met participants
may interfere with distractor trial performance by di-
minishing the ability to shield the ongoing task rule from
interference by salient distractors (i.e., reducing rule se-
lective firing) or by impairing the ability to efficiently re-
spond to incoming stimulus information (i.e., by reducing
overall firing).
This account is in contrast to the logic of the dual-state
theory (Durstewitz & Seamans, 2008), which might hold
that, by broadly increasing DA availability, the active
cortical network in Met homozygotes was shifted from
a D1-dominant to a D2-dominant state, characterized
by reduced shielding of representations from distraction,
and more frequent switches between representations.
Although enhancement of D2 signaling (i.e., following
administrat ion of bromocript ine) did increase
spontaneous switching in these participants (see below),
a comparable effect was not obtained with tolcapone.
Cued task-switching cost, a presumptively D2-mediated
facet of behavior, was likewise unaffected by tolcapone
in these individuals, and tolcapone did not interact with
Taq1A genotype (a putative marker of D2 receptor den-
sity) to influence behavior. Together, this pattern of re-
sults suggests that poorer distractor resistance in Met
homozygotes was unlikely to have been driven simply
by a transition to a D2-dominant state.
In a departure from our prediction that DA augmen-
tation would improve cognitive stability in lower DA
participants, COMT Val homozygotes did not show be-
havioral enhancement by tolcapone treatment. If Val car-
riers do, in truth, benefit cognitively from tolcapone, as
has been found in certain studies of humans and rodents
(Risbrough et al., 2014; Farrell et al., 2012; Apud et al.,
2007), it is possible that elements of task design (such
as relative difficulty) play an outsized role in determining
the presence or absence of treatment effect. For exam-
ple, using a version of an n-back task, Farrell et al.
(2012) observed tolcapone-induced perturbations in
Met participants’ performance at low levels of difficulty
(i.e., 0-back and 1-back) but improvements in Val partici-
pants’ performance only at higher levels of cognitive de-
mand (i.e., 2-back and 3-back). Thus, the distractor trials
in our task may have been sufficient to drive poorer
drug-related performance in Met homozygotes but insuffi-
ciently demanding to reveal benefits for Val homozygotes.
Indeed, it is possible that the optimal level of cortical DA
(or optimal D1/D2 ratio) required for performing our dis-
tractor task may be lower than for other paradigms. As
such, Val homozygotes may already approach the apex
of a putative inverted-U-shaped curve linking DA levels
and performance at baseline; augmentation of DA with
tolcapone might shift these participants to the opposite
side of such an apex while leaving the D1/D2 ratio itself
(and consequently the behavior) virtually unchanged.
Alternatively, distraction at the level of task rule (rather
than at the level of an individual item) may not follow
the anticipated inverted-U-shaped pattern with respect
to DA, either within the range of DA levels tested, for
the current paradigm, or at all. Indeed, recent work
(Floresco, 2013) highlights the multitude of functions re-
lating PFC DA neuromodulation to cognition.
Bromocriptine Enhances Spontaneous Switching
in High-DA Participants
In contrast to the deleterious effect of tolcapone on dis-
tractor resistance, bromocriptine did not significantly
perturb task maintenance nor did it improve cued task
switching differentially in COMT Met and Val homozy-
gotes. This result bolsters the interpretation that the
tolcapone-induced worsening of distractor resistance in
Met homozygotes, reviewed above, was mediated primar-
ily by D1, rather than D2, receptor actions. Furthermore,
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it accords with rat and nonhuman primate work demon-
strating no net effect of PFC D2 agonism on working
memory (Romanides, Duffy, & Kalivas, 1999; Sawaguchi &
Goldman-Rakic, 1994; but see Druzin, Kurzina, Malinina, &
Kozlov, 2000) or set switching (Floresco, Magyar, Ghods-
Sharifi, Vexelman, & Tse, 2006) and human PET results
indicating no relationship between PFC D2 receptor bind-
ing potential and scores on a neuropsychological battery
probing immediate and delayed stimulus recall as well
as perseveration on the Wisconsin Card Sorting Task
(Takahashi et al., 2008).
Interestingly, bromocriptine induced a higher fre-
quency of spontaneous task switches when explicit task
cues were ambiguous, but only in Met homozygotes. This
effect is not likely attributable to drug-related changes in
Met participants’ use of residual luminance difference to
guide decision-making. Although the difference in lumi-
nance between the two stimuli presented on ambiguous
trials was strongly predictive of the choice to maintain
the ongoing task or switch tasks on a given trial, it did
not interact with COMT genotype, drug, or the inter-
action of genotype and drug to explain variability in spon-
taneous switching. We propose several factors that may
bear on the extent to which D2 stimulation facilitates
cognitive flexibility as a function of COMT genotype.
First, the influence of dopaminergic activity, particularly
in the PFC, may be enhanced during the performance
of more novel actions relative to highly familiar tasks
(Puig & Miller, 2014). Although switch and ambiguous tri-
als occurred with equal frequency across the task, ambig-
uous trials were not included in participants’ training nor
did they convey clear information about the type of re-
sponse that should occur, rendering mastery unlikely.
Second, it is possible that higher levels of uncertainty
during ambiguous trials elicit changes in bottom–up sig-
naling, such as increases in mesocortical DA release (de
Lafuente & Romo, 2011), which in turn may be sufficient
to drive cognitive flexibility for the high-DA Met group
even in the absence of equivalent changes during unam-
biguous trials. Finally, the difference in drug effects may
be due to variation in the levels of hierarchical cognitive
control engaged across trial types. That is, because am-
biguous trials lack a discrete mapping between presented
stimuli and task rule, responses may rely on the biasing
influence of top–down control signals from regions en-
coding higher order policies or levels of task abstraction
(Badre & D’Esposito, 2009). Given the proposal that the
distribution of DA receptor density varies across PFC re-
gions involved in supporting hierarchical levels of cogni-
tive control (Vogelsang & D’Esposito, 2018), future work
should examine systematically how the impact of DA
drugs, such as bromocriptine, varies as distinct levels of
hierarchical control are invoked.
It is important to note the possibility that the
bromocriptine-related change in spontaneous switching
rate was due to D2 actions in the striatum as well as in
the PFC. Indeed, COMT genotype may indirectly affect
levels of DA synthesis in populations of dopaminergic
neurons projecting to the striatum; the Val allele has
been associated with increased expression of midbrain
tyrosine hydroxylase, the rate-limiting enzyme for DA
synthesis, an effect hypothesized to result from DA ac-
tions within the PFC (Akil et al., 2003). Thus, if striatal
DA synthesis (and perhaps, release) is lower in Met ho-
mozygotes, administration of an agonist targeting stria-
tal DA receptors could improve cognitive flexibility (see
discussion below), though it remains to be determined
why this pattern would only be observed for ambiguous
trials.
Bromocriptine Enhances Cued Switching in
Low-DA Participants
We hypothesized that bromocriptine would modulate cog-
nitive flexibility through actions of the DA D2 receptor. We
found that bromocriptine reduced the proportion of cued
switch trials during which Taq1A A1− homozygotes con-
tinued to perform the ongoing task (i.e. “failures to
switch”) but did not significantly affect the overall accuracy
of switch trial responses nor any measure of distractor trial
performance. This dissociation supports the idea that D2
signaling is more involved in the gating of newly relevant
task sets into working memory or in the updating of atten-
tional targets than in the accumulation of evidence in favor
of a particular response or the deployment of higher order
control more broadly. Indeed, PET studies of healthy
adults have implicated striatal D2 family receptor binding
in giving rise to successful task and rule switching. For
example, Monchi, Ko, and Strafella (2006) reported that
striatal D2 binding potential was reduced when partici-
pants performed a card classification task in which the
relevant attribute switched every trial compared with
when they performed the same task without trial-wise
switches, suggesting that, when cognitive flexibility
demands increase, so too do striatal DA release and D2
binding. Complementing this result, Samanez-Larkin
et al. (2013) observed that increases in striatal DA release
(and D2 family binding) following amphetamine adminis-
tration correlated with drug-related improvements in
cued task switching. Importantly, our drug effect was
mediated by Taq1A genotype: Only A1− homozygotes,
associated with lower striatal DA in the healthy human
striatum (Laakso et al., 2005), showed bromocriptine-
related improvements in cognitive flexibility. Such
baseline dependency accords well with other work prob-
ing the influence of striatal DA on cognitive flexibility
(van Holstein et al., 2011; Cools et al., 2007). In these
studies, the effect of D2 agonists on cognitive flexibility
has typically favored individuals posited to have lower rel-
ative striatal DA neurotransmission, leading to the hy-
pothesis that, as with D1 receptor stimulation in the
PFC, the relation between striatal DA and performance
follows an inverted-U-shaped function.
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In addition to reduced DA synthesis, the Taq1A A1−
genotype has been repeatedly associated with greater
striatal D2 receptor density in healthy adults (Gluskin &
Mickey, 2016; Savitz et al., 2013). Enhanced D2 receptor
density—a phenotype associated with impaired rule re-
versal in transgenic mice (Kellendonk et al., 2006)—
may, in fact, trigger the downregulation of DA synthesis
observed in A1− carriers (Laakso et al., 2005). Specula-
tively, by increasing striatal D2 autoreceptor density, the
Taq1A A1− genotype may attenuate phasic DA release
(Laakso et al., 2005) and consequently reduce direct path-
way excitation in response to salient environmental stimuli
(or explicit switch cues). Administering a D2 agonist could
rectify the bias toward direct pathway-mediated cognitive
flexibility in the context of salient task cues by acting on
inhibitory postsynaptic D2 receptors within the indirect
pathway. This hypothesis is partially supported by recent
evidence that stimulation of D2 family receptors in the
marmoset striatum exerts a triphasic dose-dependent ef-
fect on cognitive flexibility that may depend on relative
levels of autoreceptor stimulation (Horst, Jupp, Roberts,
& Robbins, 2019). Specifically, following infusion of
quinpirole (a D2 agonist) across a wide range of doses,
nonhuman primates exhibited a general trend of impaired
reversal learning at relatively low and high doses and a
boost in performance at medium doses. At low doses, it
was posited that behavioral decline is related to preferen-
tial occupancy of inhibitory, presynaptic D2 autoreceptors
leading to reduced striatal DA release, whereas at mid-
range doses, flexibility is facilitated by an optimal balance
of pre- and postsynaptic D2 receptors. The absolute
doses at which performance changed varied considerably
across monkeys and were related to hemispheric differ-
ences in D2 receptor binding. Thus, it is plausible that
the nonlinear relationship between striatal DA and cogni-
tive performance in humans is also mediated by relative
pre-/postsynaptic D2 binding, and as such, genetic vari-
ability in D2 receptor density would be expected to sig-
nificantly affect the outcome of a single dose of agonist
across participants. Future work exploiting genetic varia-
tion in the expression of D2 autoreceptors (Zhang et al.,
2007) may lead to a better understanding of the neural
mechanisms underlying the baseline-dependent effect
of D2 agonists on cognitive flexibility, as it has with work-
ing memory (Gelao et al., 2014; Zhang et al., 2007) and
outcome-based learning (Frank & Hutchison, 2009).
Opposing Drug Effects on Cognitive Flexibility
and Stability
Finally, we examined the extent to which DA drug admin-
istration produces opposing effects on cognitive stability
and flexibility. This idea follows from the recognition that
D1 and D2 receptors exert opposing effects on down-
stream signaling pathways in the PFC and striatum and
from work in humans demonstrating antagonistic effects
of drug on behavioral domains (e.g., impaired performance
on task switching but improved performance on distractor
resistance; Mehta, Manes, Magnolfi, Sahakian, & Robbins,
2004). In seeming contradiction to this proposal, the most
prominent relationship between the drug-driven changes in
these facets of cognitive control was one of positive corre-
lation. However, PCA revealed a secondary structure char-
acterized by antagonism between drug effects on switch
and distractor costs (specific, here, to RT costs) that was
not evident from simple correlation analysis. Thus, it is im-
portant to note that more global change in performance of
complex tasks from session to session may mask subtler
drug effects. Bromocriptine, in particular, emerged as an
elicitor of opposing influences on cognitive flexibility and
stability, despite its apparent lack of significant effect on
either domain across the entire sample and its simple ef-
fects being limited to a single domain (i.e., flexibility) when
considering genotypic subgroups. Whether this pattern is
evoked to the same extent by tolcapone is less clear; for
these data, the eigenvalue associated with the relevant com-
ponent was < 1, loadings on this component were highly
imbalanced across domains, and direct comparison with
bromocriptine’s “antagonism” component yielded low
(though present) evidence for similarity. Given that our
measure of component similarity was computed across
only four values, subsequent work with a larger set of var-
iables is needed to determine with confidence whether
these drugs vary in their ability to elicit opposing effects
on cognitive stability and flexibility. Nonetheless, these pre-
liminary results suggest that dopaminergic drugs shift the
balance between flexibility and stability and that this may
be particularly true for drugs impacting function in both
striatum and cortex or targeting D2 receptor signaling.
Importantly, the direction and magnitude of these shifts
vary across individuals. This raises the possibility that, as
with the putatively “primary” effect of a drug on per-
formance metrics (e.g., tolcapone’s influence on distractor
RT cost or bromocriptine’s effect on switch errors), baseline
differences in neurobiological structure, connectivity, and
function may moderate a particular drug’s influence. The
nature of these particular differences, as well as their re-
lationship to phenotypes contributing to primary effects
of drug in humans, comprise a promising area for future
research.
Note on Reliability
Our study included well-balanced genotype groups, direct
comparison of effects between two drugs putatively acting
on components of the DA system associated with these
genotypes, strong a priori hypotheses, and a task opti-
mized to dissociate components of hypothesized drug ef-
fects. We note that, although the genotype-mediated
results present in the data were in the anticipated direc-
tion based on inverted-U-shaped and dual-state models,
the absence of other effects predicted by these same
models and reported in other studies (e.g., lack of
tolcapone-related benefit in Val homozygotes) may be
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due to low power or sources of variability that remain un-
accounted for. Future work aimed at developing more di-
rect estimates of baseline D1 and D2 density across the
human brain (i.e., optimized PET measures) will likely
enhance our ability to evaluate and characterize baseline-
dependent effects of DA manipulations. Although the reli-
ability of the observed effects will only be determined by
replication, we believe that the results of this study
demonstrate an important dissociation in the effects of
bromocriptine and tolcapone on distinct cognitive control
processes.
Reprint requests should be sent to Daniella J. Furman, Helen
Wills Neuroscience Institute, University of California, Berkeley,
Berkeley, CA 94720, or via e-mail: dfurman@berkeley.edu.
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